Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
NCT06092645
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Bile Duct Adenocarcinoma
Interventions
DRUG:
surufatinib plus cadonilimab
Sponsor
Zhejiang Cancer Hospital